

| Catalog No. | HD002012 |
|---|---|
| Description |
Recombinant Human HPGD Protein, N-His (HD002012) expressed in E. coli, spanning Met1-Gln266. Purity: >90% by SDS-PAGE.
Highlights
|
| Expression system | E. coli |
| Accession | P15428 |
| Protein length | Met1-Gln266 |
| Applications | ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress |
| Species | Homo sapiens (Human) |
| Nature | Recombinant |
| Endotoxin level | Please contact with the lab for this information. |
| Purity | >90% as determined by SDS-PAGE. |
| Predicted molecular weight | 31.14 kDa |
| Form | Lyophilized |
| Storage buffer | Lyophilized from a solution in PBS pH 7.4, 1 mM EDTA, 4% Trehalose, 1% Mannitol. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Reconstitution | Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details. |
| Shipping | In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternate Names | 15-PGDH, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], EC:1.1.1.-, EC:1.1.1.141, EC:1.1.1.232, Eicosanoid/docosanoid dehydrogenase [NAD(+)], HPGD, PGDH1, Prostaglandin dehydrogenase 1, SDR36C1, Short chain dehydrogenase/reductase family 36C member 1 |
| Background | 15-hydroxyprostaglandin dehydrogenase [NAD(+)] is a ~28 kDa protein. Catalyzes the NAD-dependent dehydrogenation (oxidation) of a broad array of hydroxylated polyunsaturated fatty acids (mainly eicosanoids and docosanoids, including prostaglandins, lipoxins and resolvins), yielding their corresponding keto (oxo) metabolites. Decreases the levels of the pro-proliferative prostaglandins such as prostaglandin E2 (whose activity is increased in cancer because of an increase in the expression of cyclooxygenase 2) and generates oxo-fatty acid products that can profoundly influence cell function by abrogating pro-inflammatory cytokine expression. Converts resolvins E1, D1 and D2 to their oxo products, which represents a mode of resolvin inactivation. Resolvin E1 plays important roles during the resolution phase of acute inflammation, while resolvins D1 and D2 have a unique role in obesity-induced adipose inflammation. 1. Clish, CB. et al. (2000) The Journal of biological chemistry 275, 25372-80. PMID: 10837478 2. Arita, M. et al. (2006) The Journal of biological chemistry 281, 22847-54. PMID: 16757471 3. Cho, H. et al. (2006) Bioorganic & medicinal chemistry 14, 6486-91. PMID: 16828555 4. Liu, X. et al. (2011) Chemical research in toxicology 24, 2227-36. PMID: 21916491 5. Wendell, SG. et al. (2015) The Journal of biological chemistry 290, 5868-80. PMID: 25586183 6. Ensor, CM. et al. (1994) Biochimica et biophysica acta 1208, 151-6. PMID: 8086429 7. Yan, M. et al. (2004) Proceedings of the National Academy of Sciences of the United States of America 101, 17468-73. PMID: 15574495 8. Clària, J. et al. (2012) Journal of immunology (Baltimore, Md. : 1950) 189, 2597-605. PMID: 22844113 |
| Note | For research use only |
Contact us for custom quotes, bulk requests and any other issues.
Mail: [email protected]
+86-27-65523339
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский